Keytruda Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Keytruda, the brand name for Merck's pembrolizumab, is a programmed death receptor-1 (PD-1) inhibitor that has become the pharmaceutical industry's highest-grossing product. The market encompasses global sales of the drug across all approved oncology indications, with Merck reporting full-year 2025 revenue of $31.7 billion, a 7% increase over the prior year. Because no government or official statistical agency publishes dedicated market size figures for individual drugs, independent market research firms produce varying estimates ranging from approximately $23.7 billion to $36.8 billion for 2025.

• •Merck reported Keytruda global sales of $31.7 billion in 2025, marking a 7% year-over-year increase
• •Market research estimates for 2025 range from approximately $23.7 billion to $36.8 billion depending on methodology
• •No official government statistical agency publishes dedicated market size data for individual pharmaceutical products

The primary driver of market growth remains Keytruda's continually expanding FDA and international approved indications, which now span more than 20 cancer types including lung, melanoma, bladder, head and neck, and colorectal cancers. Rising global cancer incidence, an aging population, and Keytruda's favorable reimbursement status in major markets including the United States, Europe, and Japan sustain demand. Additional growth comes from first-line combination therapies and new adjuvant settings where Keytruda is used to prevent cancer recurrence after surgery.

• •Expansion into new approved indications and combination therapies continues to widen the addressable patient population
• •Patent protection in major markets until 2028 in the U.S. and beyond in other regions supports brand pricing power
• •Strong clinical evidence across multiple tumor types has established Keytruda as a backbone therapy in oncology treatment guidelines

The United States represents the largest single market for Keytruda, accounting for the majority of global sales due to favorable pricing, broad insurance coverage, and high cancer treatment adoption rates. Europe, Japan, and emerging markets in Asia-Pacific follow, with growth rates varying by regulatory approval timelines, healthcare infrastructure, and pricing pressures. Patent expiry timelines differ significantly by country, with biosimilar entry expected first in Europe and later in the United States following the 2028 patent cliff.

• •North America dominates global Keytruda revenue, with the United States representing the largest geographic market
• •Patent expiry in the U.S. is expected around 2028, while European biosimilar competition may arrive earlier
• •Emerging markets in Asia-Pacific and Latin America represent growing opportunities as healthcare access expands

What are the recent trends and outlook?

The market faces a well-documented patent cliff beginning around 2028 in the United States, which will introduce biosimilar competition and exert meaningful pressure on pricing and revenue. Long-term market forecasts vary considerably depending on the pace of biosimilar uptake, with projections ranging from modest growth to contraction through the early 2030s. Merck is actively developing its next-generation oncology pipeline, including the T-cell engager vilastobul and other immunotherapies, to offset the eventual decline in Keytruda revenue, while continued label expansion and new combination approvals may help sustain the drug's commercial performance through the late 2020s.

• •U.S. patent expiry around 2028 will introduce biosimilar competition and is expected to reduce branded Keytruda revenue over time
• •Merck is developing a diversified oncology pipeline to offset Keytruda revenue decline in the post-patent period
• •Further FDA approvals in new indications and earlier-line treatment settings could extend Keytruda's commercial peak